Skip to content

Cosmetic Effects of Topical Acetyl Zingerone

Randomized Double-Blind Study of the Cosmetic Effects of Topical Acetyl Zingerone

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03530787
Enrollment
31
Registered
2018-05-21
Start date
2017-12-11
Completion date
2018-10-12
Last updated
2019-01-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erythema, Lipidome, Microbiome, Side Effect, Skin Pigment, Wrinkle Appearance

Keywords

Ginger, Curcumin, Zingerone

Brief summary

Cosmeceuticals are an emerging market within dermatology and the growth of natural products and derivatives of natural products has accelerated in use within the field. Here the investigators aimed to study the microbial and cosmetic effects of Synoxyl AZ, the trade name for topical acetyl zingerone (AZ), a novel compound designed based on Zingerone and curcumin.

Detailed description

Cosmeceuticals are an emerging market within dermatology and the growth of natural products and derivatives of natural products has accelerated in use within the field. Here the investigators aim to study Synoxyl AZ, the trade name for topical acetyl zingerone (AZ), a novel compound designed based on Zingerone and curcumin. Both curcumin and Zingerone are from the Zingiberacea family of plants (also known as the ginger family). Both have been widely studied and noted to have antibacterial effects and promote skin health effects. Curcumin has been studied widely in recent years due to various microbial effects. AZ is a derivative that is similar to both Zingerone and curcumin and has been noted to have many different activities including anti-inflammatory, antimicrobial, and antioxidant functions. However, there are no studies looking at how it modulates the skin cosmetically or the superficial microbiome. The aim of this study was to compare the cosmetic effects of AZ to a vehicle over an 8-week period.

Interventions

OTHERAcetyl Zingerone Topical Cream

Topical cream with an active acetyl zingerone component.

Topical cream without an active acetyl zingerone component and just the carrier cream.

Sponsors

University of California, Davis
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Masking description

Double blind

Intervention model description

Subjects will be randomized to two groups: AZ Group (n= 17) Control Group (n=17)

Eligibility

Sex/Gender
ALL
Age
30 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* Individuals aged 30-60 * Healthy subjects

Exclusion criteria

* Those that have had topical antibiotics within the past 4 weeks * Those that have had oral antibiotics within past 4 weeks * Those who have used systemic isotretinoin in the last 6 months * Those with a known allergy to members of the ginger family * Current smokers OR 20 pack-year history of smoking OR Have smoked within the past 3 years * Pregnant women * Prisoners * Those who have had any change to their hormonal birth control regimen in the last 4 weeks. * Those with visible signs in the area of application of or on active treatment for cystic acne, eczema, seborrheic dermatitis, papulopustular rosacea at investigator discretion * Those who have had a recent surgical or cosmetic procedure in the last 3 months that can affect facial wrinkles or facial hyperpigmentation, such as botulinum toxin injections, chemical peels, laser based therapies to the face, or face lift surgeries at investigator discretion

Design outcomes

Primary

MeasureTime frameDescription
Change in wrinkle appearance8 weeksChange in image based analysis of wrinkle severity from baseline
Change in appearance of skin pigmentation8 weeksChange in appearance of image based skin pigmentation from baseline

Secondary

MeasureTime frameDescription
Change in wrinkle appearance4 weeksChange in image based analysis of wrinkle severity from baseline
Appearance of side effects such as scaling or irritation4 weeks and 8 weeksAppearance of side effects such as scaling or irritation from baseline
Change in skin redness (erythema)4 weeks and 8 weeksChange in image based skin redness (erythema) and clinical assessment of redness from baseline
Change in superficial lipidome diversity4 weeks and 8 weeksChange in superficial lipidome diversity from basline
Change in superficial microbiome diversity4 weeks and 8 weeksChange in superficial microbiome diversity from baseline
Change in appearance of skin pigmentation4 weeksChange in appearance of image based skin pigmentation from baseline

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026